Imetelstat Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 47 mg, 188 mg
Reference Brands: Generic formulations marketed under different names
Category:
Oncology Cancer Care
Imetelstat is available in Injection
and strengths such as 47 mg, 188 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Imetelstat is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Imetelstat can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Imetelstat sodium is a targeted anti-cancer therapy used in the treatment of myelodysplastic syndromes (MDS) associated with transfusion-dependent anemia. It is marketed under the brand name Rytelo and represents a first-in-class telomerase inhibitor designed to address the underlying disease biology rather than only managing symptoms. Imetelstat is an oligonucleotide-based medication developed to selectively inhibit telomerase, an enzyme that is highly active in rapidly dividing cells, including malignant cancer cells.
Telomerase plays a crucial role in maintaining telomere length, allowing cancer cells to continue dividing uncontrollably. By blocking telomerase activity, imetelstat causes progressive telomere shortening, which limits the ability of malignant stem and progenitor cells to proliferate. This process ultimately leads to cancer cell death and a reduction in abnormal cell clones responsible for disease progression. Through this mechanism, imetelstat helps improve bone marrow function and reduces transfusion dependence in eligible patients.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing